Ireland
--:--IST
Recruiting Observational

Pharmacogenetics of Antidepressant-Induced Disinhibition

NCT03953014 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2019-01-02
Last updated
2026-05-14

Condition(s) studied

Obsessive-Compulsive DisorderAnxiety DisordersMajor Depressive DisorderAntidepressant Drug Adverse Reaction

Study summary

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 6 - 24 years 2. Medical records available 3. Diagnosis of MDD, anxiety disorder, or OCD 4. Current or past history of SSRI therapy Exclusion Criteria: 1. Inability of parent/legal guardian to give informed consent 2. Inability of the child to give informed assent 3. Unwillingness of child to provide saliva sample for genetic analysis 4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.

Primary outcome measure(s)

  • Genetic variants in SSRI metabolism — 4 years
    DNA Sample Collection \& Genotyping. Saliva will be collected using Oragene® collection tubes (DNA Genotek, Ottawa, Canada). DNA will be extracted using standard procedures and genotyped.
  • Behavioural Disinhibition — 4 years
    Information on behavioural disinhibition (BD) to note the type, duration and severity of BD gathered from medical records, and participant and parent report. The Treatment-emergent activation and suicidality assessment profile (TEASAP), is a questionnaire that assess common symptoms of activation syndrome/behavioural disinhibition in youth due to SSRI usage.

Trial sites (1)

FacilityCityRegionStatus
Child and Adolescent Addiction, Mental Health & Psychiatry Calgary Alberta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03953014 on ClinicalTrials.gov ↗ ← All trials in Canada